60 patients with stage III-IV NSCLC will be randomly divided into group A (receive DC-CTL treatment with chemotherapy) or group B (Just receive chemotherapy), and the randomize ratio will be 1:1, patients in group A will receive 3 cycles of DC-CTL treatment (every 1 months) and 4 cycles of chemotherapy (every 2 weeks). Patients in group B will receive only 4 cycles chemotherapy(every 2 weeks).
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient who have signed the informed consent;
Histologically confirmed with NSCLC at stage III-IV
Expected survival time is more than 2 month;
Eastern Cooperative Oncology Group(ECOG) performance status was 0-2
You may not be if
Hemoglobin \<8.0 g/dL, White blood cell \<3 x 10\^9/L; Platelet count \<75 x 10\^9/L; alanine aminotransferase(ALT), aspartate aminotransferase(AST), blood urea nitrogen(BUN) and Creatinine(CR) more than normal limits on 3.0 times;
Known or suspected allergy to the investigational agent or any agent given in association with this trial;
Pregnant or lactating patients;
Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection;
Patients who are suffering from serious autoimmune disease;
Patients who had used long time or are using immunosuppressant;
Patients who had active infection;
Patients who are suffering from serious organ dysfunction;
Patients who are suffering from other cancer;
Other situations that the researchers considered unsuitable for this study.